A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients

Oncology

Volumn 58, Issue 4, 2000, Pages 324-333

  Gradishar, William J ^a,b   Soff, Gerald ^a   Liu, Jiangou ^a   Cisneros, Angela ^a   French, Suzanne ^a   Rademaker, Alfred ^a   Benson III, Al B ^a   Bouck, Noel ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

Antiangiogenesis; Breast cancer; Suramin

Indexed keywords

ANGIOGENESIS INHIBITOR; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; MITOMYCIN; PACLITAXEL; RALOXIFENE; SURAMIN; TAMOXIFEN;

ADULT; ANEMIA; ANGIOGENESIS; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST METASTASIS; CAPILLARY ENDOTHELIUM; CELL MIGRATION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; LABORATORY TEST; LYMPHOCYTOPENIA; NAUSEA; NONHUMAN; PARALYSIS; PATIENT MONITORING; PLASMA; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA;

EID: 0034062773     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000012120     Document Type: Article

References (62)

1. Honig SH: Treatment of metastatic disease; in Harris JR, Lippman ME, Morrow M, Hellman S (eds): Diseases of the Breast, Philadelphia, Lippincott-Raven, 1996, pp 649-734.
2. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-1186.
3. Folkman J: Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-1761
4. Bouck N, Stellmach V, Hsu SC: How tumors become angiogenic. Adv Cancer Res 1996;69: 135-174.
5. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-328.
6. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285.
7. Boehm T, Folkman J, Browder T, O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:335-336.
8. Gibson DW: Histopathological studies on suramin toxicity in a chimpanzee. Tropenmed Parasit 1997;28:397-405.
9. LaRocca RV, Meyer CE: Suramin: Prototype of a new generation of antitumor compounds. Cancer Cells 1990;2:106-115.
10. Voogd TE, Vansterkenburg ELM, Wilting J, Janssen LHM: Recent research on the biological activity of suramin. Pharmacol Rev 1993; 45:177-203.
11. Fantini J, Venier B, Robert C, Pic P, Pichon J, Mauchamp J, Marvaldi J: Suramin-induced differentiation of the human colic adenocarcinoma cell clone HT 29-D4 in serum free medium. Exp Cell Res 1990;189:109-117.
12. Vignon F, Prebois C, Rochefort H: Inhibition of breast cancer growth by suramin. J Natl Cancer Inst 1992;84:38-42.
13. Coomber BL: Suramin inhibits C6 glioma-induced angiogenesis in vitro. J Cell Biochem 1995;58:199-207.
14. Eisenberger MS, Sinibaldi VJ, Reyno LM, Sridhara R, Jodrell DI, Zuhowski EG, Tkaczuk KH, Lowitt MH, Hemady RK, Jacobs SC, Van Echo D, Egorin MJ: Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J Clin Oncol 1995;13:2174-2186.
15. Kobayashi K, Vokes EE, Vogelzang NJ, Janisch L, Soliven B, Ratain MJ: Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J Clin Oncol 1995;13:2196-2207.
16. Scher H, Kelly WK: Suramin: Defining the role in the clinic. Princ Pract Oncol 1993;7:1-16.
17. Dawson NA, Figg WD, Cooper MR, Sartos O, Bergan RC, Semderowicz AM, Steinberg SM, Tompkins A, Weinberg B, Sausville EA, Reed E, Myers CE: Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic breast cancer. J Clin Oncol 1997;15: 1470-1477.
18. Bowden CJ, Figg WD, Dawson NA, Sartor O, Bitton RG, Weinberger MS, Headlee D, Reed E, Myers CE, Cooper, MR: A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer. Toxicity and response. Cancer Chemother Pharmacol 1996;39:1-8.
19. Rosen PJ, Mendoza EF, Landaw EM, Mondino B, Graves MD, McBride JH, Turcillo P, DeKernion J, Belldegrun A: Suramin in hormone-refractory metastatic prostate cancer: A drug with limited efficacy. J Clin Oncol 1996; 14:1626-1636.
20. Dawson NA, Cooper MR, Figg WD, Headlee DJ, Thibault A, Bergan RC, Steinberg SM, Sausville EA, Myers CE, Sartor O: Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer 1995;76: 453-462.
21. Kelly WK, Curley T, Leibretz C, Dnistrian A, Schwartz M, Scher HI: Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J Clin Oncol 1995;13:2208-2213.
22. Reyno LM, Egorin NJ, Eisenberger MA, Sinibaldi VJ, Zubowski EG, Sridhara R: Development and evaluation of a pharmacokinetically based fixed dosing scheme for suramin. J Clin Oncol 1995;13:2187-2195.
23. Eisenberger MA, Reyno LM, Jodrell DI, Sinibaldi VJ, Tkaczuk KH, Sridhara R, Zuhowski EH, Lowitt MH, Jacobs SC, Egorin MJ: Suramin, an active drug for prostate cancer: Interim observations in a phase I trial. J Natl Cancer Inst 1993;85:611-621.
24. Myers CE, Cooper MR, Stein CA, LaRocca R, Walther MM, Weiss G, Choyke P, Dawson N, Steinberg S, Uhrich MM, Cassidy J, Kohler DR, Trepel J, Linehan WM: Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 1992;10:881-889.
25. Coffey RJ, Leof EB, Shipley GD, Moses HL: Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. J Cell Physiol 1987;132:143-148.
26. Vincent TS, Hazen-Martin DJ, Garvin AJ: Inhibition of insulin like growth factor II autocrine growth of Wilms' tumor by suramin in vitro and in vivo. Cancer Lett 1996;103:49-56.
27. Braddock PS, Hu DE, Fan TP, Stratford IJ, Harris AL, Bicknell R: The structure-activity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanions. Br J Cancer 1994;69:890-898.
28. Takano S, Gately S, Neville ME, Herbilin WF, Gross JL, Engelhard H, Perricone M, Eidsvoog K, Brem S: Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation and induction of urokinase-type plasminogen activator. Cancer Res 1994;54:2654-2660.
29. Danesi R, Del Bianchi S, Soldani P, Campagni A, LaRocca RV, Myers CE, Paparelli A, Del Tacca M: Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane. Br J Cancer 1993;68:932-938.
30. Stein CA: Suramin: A novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res 1993;53:2239-2248.
31. Bikfalvi A, Sauzeau C, Moukadiri H, Maclouf J, Busso N, Bryckaert M, Plouet J, Tobelem G: Interaction of vasculotropin/vascular endothelial cell growth factor with human umbilical vein endothelial cells: Binding, internalization, degradation and biological effects. J Cell Physiol 1991;149:50-59.
32. Waltenberger J, Mayr U, Frank H, Hombach V: Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution of the molecular basis of antiangiogenic action. J Mol Cell Cardiol 1996;28:1523-1529.
33. Brown KJ, Maynes SF, Bezos A, Maguire DJ, Ford MD, Parish CR: A novel in vitro assay for human angiogenesis. Lab Invest 1996;75:539-555.
34. Garrido T, Riese, HH, Aracil M, Pesez-Aranda A: Endothelial cell differentiation into capillary-like structures in response to tumor cell conditioned medium: A modified chemotaxis chamber assay. Br J Cancer 1995;761:770-775.
35. Nakamura S, Sakurada S, Salahuddin SZ, Osada Y, Tanaka NG, Sakamoto N, Sekiguchi M, Gallo RC: Inhibition of development of Kaposi's sarcoma-related lesions by a bacterial wall complex. Science 1992;255:1437-1440.
36. Firsching A, Nickel P, Mora P, Allolio B: Anti-proliferative and angiostatic activity of suramin analogues. Cancer Res 1995;55:4957-4961.
37. Ciomei M, Pastori W, Mariani M, Sola F, Grandi M, Mongelli N: New sulfonated distamycin A derivatives with bFGF complexing activity. Biochem Pharmacol 1994;47:295-302.
38. Gagliardi A, Hadd H, Colllins DC: Inhibition of angiogenesis by suramin. Cancer Res 1992; 52:5073-5075.
39. Leikens S, Neyts J, Degreve B, DeClercq E: The sulfonic acid polymers PAMPS [poly(2-acrylamido-2-methyl-1-propanesulfonic acid)] and related analogues are highly potent inhibitors of angiogenesis. Oncol Res 1997;9:173-181.
40. Hu DE, Fan TP: Suppression of VEGF-induced angiogenesis by the protein tyrosine kinase inhibitor, lavendustin A. Br J Pharmacol 1995;114:262-268.
41. Okada N, Fushimi M, Nagata Y, Fukunaga T, Tsutsumi Y, Nakagawa S, Mayumi T: Evaluation of angiogenic inhibitors with an in vivo quantitative angiogenesis method using agarose microencapsulation and mouse hemoglobin enzyme-linked immunosorbent assay. Jpn J Cancer Res 1996;87:952-957.
42. Gil M, Skopinska-Rozewska E, Radomska D, Demkow U, Skurzak H, Rochowska M, Beuth J, Roszkowski K: Effect of purinergic receptor antagonists suramin and theobromine on tumor-induced angiogenesis in BALB/c mice. Folia Biol 1993;39:63-68.
43. Pesenti E, Sola F, Mangelli N, Grandi M, Spreafico F: Suramin prevents neovascularization and tumor growth through blocking of basic fibroblast growth factor activity. Br J Cancer 1992;66:367-372.
44. Clinical Pharmacology Resource Facility, University of Texas, MD Anderson Cancer; Houston.
45. Teirlynck O, Bogaert MG, Demedts P, Taelman H: Rapid high-performance liquid chromatographic determination of suramin in plasma of patients with acquired immune deficiency syndrome (AIDS) or AIDS-related complex (ARC). J Pharm Biomed Anal 1989;72:123-126.
46. Masson E, Zamboni WC: Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes. Clin Pharmacokinet 1997;32:324-343.
47. Volpert OV, Dameron KM, Bouck N: Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorgenicity. Oncogene 1997;14:1495-1502.
48. Rago RP, Miles JM, Sufit RL, Spriggs DR, Wilding G: Suramin-induced weakness from hypophosphatemia and mitochondrial myopathy. Cancer 1993;73:1954-1959.
49. La Rocca RV, Meer J, Gilliatt RW, Stein CA, Cassidy J, Myers CE, Dalakas MC: Suramin-induced polyneuropathy. Neurology 1990;40: 954-960.
50. Bitton RJ, Figg WD, Venzon DJ, Dalakas MC, Bowden C, Headlee D, Reed E, Myers CE, Cooper MR: Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin. J Clin Oncol 1995;613:2223-2229.
51. Sridhara R, Eisenberger MA, Sinibaldi JV, Reyno LM, Egorin MJ: Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J Clin Oncol 1995;13: 2944-2953.
52. Smith DC, Pienta KJ: The use of prostate-specific antigen as a surrogate end point in the treatment of patients with hormone refractory prostate cancer. Urol Clin North Am 1997;24: 433-437.
53. Harris AL, Zhang H, Moghaddan A, Fox S, Scott P, Pattison A, Gatter K, Stratford I, Bicknell R: Breast cancer angiogenesis - New approaches to therapy via antiangiogenesis, hypoxic activated drugs and vascular targeting. Breast Cancer Res Treat 1996;38:97-108.
54. Dickson RB, Lippman ME: Growth factors in breast cancer. Endocr Rev 1995;16:559-589.
55. Lee AV, Yee D: Insulin-like growth factors and breast cancer. Biomed Pharmacother 1995;49: 415-421.
56. Doughaday WH: The possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors. Endocrinology 1990; 127:1-4.
57. Lawrence JB, Conover CA, Haddad TC, Ingle JN, Reid JM, Ames MM, Suman VJ, Marks RS, Ehrlichman C, Hartman LC: Evaluation of continuous infusion suramin in metastatic breast cancer: Impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins. Clin Cancer Res 1997;3:1713-1720.
58. Miglietta L, Barreca A, Repetto L, Costantini M, Rosso R, Boccardo F: Suramin and plasma insulin-like growth factor levels in metastatic cancer patients. Anticancer Res 1993;13:2473-2476.
59. Kakeji Y, Teicher BA: Preclinical studies of the combination of angiogenic inhibitor with cytotoxic agents. Invest New Drugs 1997;15:39-48.
60. Teicher BA, Emi Y, Kakeji Y, Northey D: TNP-470/minocydine/cytotoxic therapy: A systems approach to cancer therapy. Eur J Cancer 1996;32A:2461-2466.
61. Jain RK, Schlenger K, Höckel M, Yuan F: Quantitative angiogenesis assays: Progress and problems. Nat Med 1997;11:1203-1208.
62. Wilks JW, Scott PS, Vrba LK, Cocuzza JM: Inhibition of angiogenesis with combination treatments of angiostatic steroids and suramin. Int J Radiat Biol 1991;60:73-77.